SEGMENT INFORMATION

12 Months Ended

Dec. 31, 2024

SEGMENT INFORMATION

SEGMENT INFORMATION

NOTE 13 – SEGMENT INFORMATION

a. The Company operates in Israel as a single operating segment. The Company’s President and Chief Executive Officer is the CODM. The CODM makes decisions on resource allocation, assesses performance of the business and monitors budget versus actual results on a consolidated basis.

b. Segment information:

	Year Ended December 31,
(U.S. dollars in thousands)	2022		2023		2024
Revenues from customers	$	47,638	$	65,494	$	53,399
Less:
Employee salaries and related expenses		19,388		24,075		21,780
Sub-contractors expense		24,181		14,008		8,682
interest expense		2,529		3,180		1,062
Interest income		(1,146)		(1,286)		(1,299)
Depreciation		1,086		1,191		1,304
Other segment expenses*		15,997		15,760		17,716
Income before income taxes		(14,397)		8,566		4,154
Taxes on income		530		254		1,222
Segment net income	$	(14,927)	$	8,312	$	2,932

* Other expenses included in net income includes raw materials, rent and utilities and others.

c. The following table summarizes the Company’s disaggregation of revenues:

		Year Ended December 31,
(U.S. dollars in thousands)	2022		2023		2024
Gaucher disease:
Pfizer (Ireland)	$	12,403	$	12,522	$	12,617
Fiocruz (Brazil)	$	9,452	$	10,401	$	11,031
Fabry disease:
Chiesi (Italy)	$	3,437	$	17,495	$	29,333
Total revenues from selling goods	$	25,292	$	40,418	$	52,981
Revenues from license and R&D services	$	22,346	$	25,076	$	418

d. Long lived assets are located in Israel.